S Roussin1, C Mazouni2, F Rimareix3, C Honoré1, P Terrier4, O Mir5, J Dômont5, C Le Péchoux6, A Le Cesne5, S Bonvalot7. 1. Department of Surgical Oncology, Sarcoma Unit, Gustave Roussy Cancer Center, Grand Paris, France. 2. Department of Surgical Oncology, Breast and Plastic Surgery Unit, Gustave Roussy Cancer Center, Grand Paris, France. 3. Department of Surgical Oncology, Breast and Plastic Surgery Unit, Gustave Roussy Cancer Center, Grand Paris, France; Department of Surgical Oncology, Sarcoma Unit, Gustave Roussy Cancer Center, Grand Paris, France. 4. Department of Pathology, Gustave Roussy Cancer Center, Grand Paris, France. 5. Department of Medical Oncology, Sarcoma Unit, Gustave Roussy Cancer Center, Grand Paris, France. 6. Department of Radiation Oncology, Gustave Roussy Cancer Center, Grand Paris, France. 7. Department of Surgical Oncology, Sarcoma Unit, Gustave Roussy Cancer Center, Grand Paris, France. Electronic address: sylvie.BONVALOT@gustaveroussy.fr.
Abstract
AIM: To report initial results of observation as well as surgery in patients with desmoid tumors (DTs) of the breast, a rare tumor for which data are scarce. PATIENTS AND METHODS: The initial approaches were categorized as either front-line loco-regional treatment [(surgery or radiotherapy group, SRG) n = 20] or initial observation [(no surgery/no radiotherapy group, NSRG) n = 11]. RESULTS: A total of 27 women and 4 men were assessed between 1992 and 2013 and included in this study. Patient characteristics were adequately balanced in the 2 groups. Fifteen patients (48.4%) had a past history of breast surgery in the previous 24 months. The median initial DT size on MRI was 50 mm. The median follow-up was 36 months. In the SRG, 8/20 patients (40%) experienced recurrence. The median time to recurrence was 29 months. During the study period, 6 patients in the SRG (30%) received a mastectomy at the time of diagnosis (n = 3) or at relapse (n = 3), 7 patients (35%) received a thoracic wall resection and 8 patients (40%) received radiotherapy at the time of diagnosis (n = 2) or at recurrence (n = 5). In the NSRG, the median tumor size change was -4 mm (range -13 to +20). Three patients changed treatment strategies during the observation period; one received surgery, and 2 were administered anti-hormonal treatment. CONCLUSIONS: Loco-regional treatments of breast DTs resulted in undesired disfigurement. Front-line observation yielded encouraging results and could enable the identification of patients who require loco-regional treatment. This strategy needs further evaluation.
AIM: To report initial results of observation as well as surgery in patients with desmoid tumors (DTs) of the breast, a rare tumor for which data are scarce. PATIENTS AND METHODS: The initial approaches were categorized as either front-line loco-regional treatment [(surgery or radiotherapy group, SRG) n = 20] or initial observation [(no surgery/no radiotherapy group, NSRG) n = 11]. RESULTS: A total of 27 women and 4 men were assessed between 1992 and 2013 and included in this study. Patient characteristics were adequately balanced in the 2 groups. Fifteen patients (48.4%) had a past history of breast surgery in the previous 24 months. The median initial DT size on MRI was 50 mm. The median follow-up was 36 months. In the SRG, 8/20 patients (40%) experienced recurrence. The median time to recurrence was 29 months. During the study period, 6 patients in the SRG (30%) received a mastectomy at the time of diagnosis (n = 3) or at relapse (n = 3), 7 patients (35%) received a thoracic wall resection and 8 patients (40%) received radiotherapy at the time of diagnosis (n = 2) or at recurrence (n = 5). In the NSRG, the median tumor size change was -4 mm (range -13 to +20). Three patients changed treatment strategies during the observation period; one received surgery, and 2 were administered anti-hormonal treatment. CONCLUSIONS: Loco-regional treatments of breast DTs resulted in undesired disfigurement. Front-line observation yielded encouraging results and could enable the identification of patients who require loco-regional treatment. This strategy needs further evaluation.
Authors: Michael R Boland; Timothy Nugent; Jack Nolan; Johnny O'Mahony; Sylvia O'Keeffe; Charles C Gillham; Aoife Maguire; James Geraghty; Damian McCartan; Denis Evoy; Ruth S Prichard; Enda W McDermott; Dhaffir Alazawi; Terence J Boyle; Elizabeth M Connolly Journal: Breast Cancer Date: 2020-08-11 Impact factor: 4.239
Authors: Jörn Lorenzen; Miriam Cramer; Nina Buck; Kay Friedrichs; Kirsten Graubner; Clara Sonja Lühr; Christoph Lindner; Axel Niendorf Journal: Breast Care (Basel) Date: 2020-05-28 Impact factor: 2.860
Authors: B Kasper; C Baumgarten; J Garcia; S Bonvalot; R Haas; F Haller; P Hohenberger; N Penel; C Messiou; W T van der Graaf; A Gronchi Journal: Ann Oncol Date: 2017-10-01 Impact factor: 32.976
Authors: Sara Silva; Pedro Lage; Francisco Cabral; Rui Alves; Ana Catarino; Ana Félix; Saudade André Journal: Oncol Lett Date: 2018-05-31 Impact factor: 2.967